Resources

Relation Therapeutics announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis

As 2024 comes to a close, we’re proud to reflect on a year of championing the life sciences sector, from driving impactful policy changes to fostering connections across the UK and beyond. Dive into our key achievements, events, and milestones that shaped the year and set the stage for an exciting 2025.

Cancer Research Horizons, the innovation arm of Cancer Research UK, is partnering with Diamond Light Source, the UK’s national synchrotron, to build a world-leading fragment-based drug discovery programme.

As we engage as an Association in the development of the life science sector plan, the 10 year NHS plan and the UK’s industrial strategy this winter, this week I’ve been reflecting on what recent NHS announcements on adoption of innovation tell us.

Innovating manufacturing processes is key to revolutionising access to advanced cell and gene therapies - this blog explores how Tolemy Bio's co-founders, Caelan and Alex, are leveraging cutting-edge technologies like AI, biochemical modelling, and omics data to overcome complex challenges and drive global scalability.

BIA today announces Blood Cancer UK as its charity partner of the year for 2025. This partnership demonstrates BIA’s commitment to driving meaningful change through collaboration.

When comparing the UK’s RNA manufacturing capability now, to that of before COVID-19, it is obvious that great advancements have been made. Abby Clark, Senior Manufacturing Programme Executive at the BIA, reflects on the past (nearly) five years and highlights recent work in the area.  

Stablepharma Named Life Sciences Innovation Awards Winner by Leading US News Platform, Fierce Pharma, in the “Biotech Innovation” Category

OMass Therapeutics Strengthens its Leadership Team with the Promotions of Hsin Loke to Chief Operating officer and Jon Roffey to Senior Vice President, Discovery and Non-Clinical

Today, deepmirror has raised $2.4 million to simplify the adoption of AI for molecule design and enable every company to get drugs to patients faster with their accessible AI-powered platform.

Abselion, an innovator in automated analytical instrumentation that simplifies at-line protein quantification, has secured £6.6 million in Series A financing to bring its award-winning Amperia system to market.

UCL’s Policy Impact Unit, who work closely with researchers in VaxHub Sustainable, VaxHub Global and the FTHM Hub, have recently published a position paper.

With a new Labour Government in place, this year’s event set the stage for impactful collaboration with MPs and policymakers. Read on to learn how we’re keeping life sciences at the top of the agenda.

Coulter Partners successfully completed a search assignment for Curve Therapeutics (“Curve”) and is pleased to announce the placement of Rab Prinjha, PhD, as Chief Research and Development (R&D) Officer.

The potential presented by Engineering Biology (EngBio), both globally and for the UK, is difficult to overstate. Realisation of this potential across sectors as diverse as health, energy, materials, chemicals production and waste management, will be achieved by providing the right tools to help companies of all sizes as they innovate and translate those innovations to commercial scale.

The Innovation Ecosystem Programme, an 18-month-long NHS England project, which the BIA have been involved in throughout, describes how the UK can lead the way globally in health gains and life sciences powered growth. Its final report was published last week.

Brainomix, a pioneer in artificial intelligence (AI) imaging solutions, has been awarded the LSX European Lifestars Award for “Healthtech Company of the Year” by HSBC Innovation Banking, and the “Most Transformative Healthtech Company of the Year” by OBN.

Therakind announces that the United States Patent and Trademark Office has granted a patent protecting the Company’s novel multi-dose, needle-free version of its dry powder nasal drug delivery system, DriDose®.

Stablepharma are delighted to announce that they have been selected to be part of Innovate UK’s prestigious Scaleup Programme, recognising the company's potential to grow exponentially and scale globally.